A changing landscape for companion diagnostics

Expert Review of Molecular Diagnostics

Volumn 13, Issue 7, 2013, Pages 667-669

  Jørgensen, Jan Trøst ^a  

^a Dx Rx Institute   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CAPECITABINE; CRIZOTINIB; DNA; GEFITINIB; LAPATINIB; PACLITAXEL; PHARMACOLOGICAL BIOMARKER; TRASTUZUMAB; VEMURAFENIB;

CANCER RESISTANCE; CONFERENCE PAPER; DIAGNOSTIC TEST; DNA DETERMINATION; DNA SEQUENCE; DRUG APPROVAL; EUROPE; FOOD AND DRUG ADMINISTRATION; FRANCE; GENE EXPRESSION; GENE MUTATION; HEALTH CARE COST; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MOLECULAR DIAGNOSIS; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; NATIONAL HEALTH ORGANIZATION; NEOPLASM; POLYMERASE CHAIN REACTION; SCREENING; SYMPOSIUM; TUMOR BIOPSY; BLOOD; EARLY DIAGNOSIS; NEOPLASMS;

DNA; EARLY DETECTION OF CANCER; HUMANS; NEOPLASMS;

EID: 84894593458     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2013.834799     Document Type: Conference Paper

References (6)

1. Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heel of cancer. Science 297, 63-634 (2002).
2. Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 68, 3077-3080 (2008).
3. Jørgensen JT. Companion diagnostics in oncology ~ current status and future aspects. Oncology 85, 59-68 (2013).
4. Nowak F, Soria JC, Calvo F. Tumour molecular profiling for deciding therapy-the French initiative. Nat. Rev. Clin. Oncol. 9, 479-486 (2012).
5. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 11, 426-437 (2011).
6. Murtaza M, Dawson SJ, Tsui DW et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108-112 (2013).